Mumps Diagnosis (anti-mumps IgM, IgG)

Reporting Name


Useful for

Anti-mumps IgG is an indicator of successful mumps virus vaccination, indicator of prior mumps virus exposure, and necessary to document seroconversion as confirmation of new infection. Anti-mumps IgM is an indicator of recent or current infection with mumps virus.

 

Indications for Testing

·         Differential diagnosis of parotitis, orchitis, meningitis, and deafness

 

Method Name

IgM- and IgG enzyme-linked immunosorbent assay (ELISA)

 

Reporting Name

Mumps IgG

Mumps IgM

 

Aliases

Mumps

Parotitis

Orchitis

Oophoritis

Specimen Required

Serology: Suitable specimens are individual samples (human sera or EDTA/heparinized/citrated plasma) obtained by standard laboratory techniques.

 

Specimen Minimum Volume

0.6ml

 

Transport Temperature

Specimen Room temperature Refrigerated Frozen
Serum NO YES* YES**

*The samples should be stored for not more than 3 days at 2-8°C.

**For longer delay, freeze at -70°C and transport on dry ice.

 

Reject Due To

Specimens other than Serum
Anticoagulants OK
Hemolysis OK
Lipemia OK
Icteric OK

Useful for

Anti-mumps IgG is an indicator of successful mumps virus vaccination, indicator of prior mumps virus exposure, and necessary to document seroconversion as confirmation of new infection. Anti-mumps IgM is an indicator of recent or current infection with mumps virus.

 

Clinical Information

Mumps virus, together with parainfluenza types 1 through 4, respiratory syncytial virus, and measles virus are classified in the family Paramyxovirdae. Mumps is an acute infection which causes the painful enlargement of the salivary glands in approximately 70% to 90% of children (4-15 years of age) who develop clinical disease. In 5% to 20% of postpubertal individuals, testicular pain (orchitis in males) and abdominal pain (oophoritis in females) can occur. Other complications include pancreatitis (<5% of cases) and central nervous system disease (meningitis/encephalitis) that occur rarely (about 1 in 6,000 cases of mumps).

 

Widespread routine immunization of infants with attenuated mumps virus has changed the epidemiology of this virus infection. Since 1989, there has been a steady decline in reported mumps cases, with and average of 265 cases each year since 2001. However, a recent outbreak of mumps in 2006 re-emphasized that this virus continued to persist in the population, and laboratory testing may be needed in clinically compatible situations.

 

When mumps was a common disease of childhood, the diagnosis was made largely on clinical grounds alone. With the decrease in incidence of mumps, many physicians no longer readily recognize the symptoms. In addition, typical clinical signs and symptoms may be absent in under immunized or immunocompromised individuals. Therefore, laboratory confirmation of mumps virus infection is now more important in making the diagnosis.

 

The laboratory diagnosis of mumps is typically accomplished by detection of antibody to mumps virus. However, due to the limitations of serology (eg, inadequate sensitivity and specificity), additional laboratory testing including virus isolation or detection of viral nucleic acid by PCR in throat, saliva or urine specimens should be considered in clinically compatible situations.

 

Reference Values

Anti-mumps IgG

Nonimmune individuals: Non-reactive

Immune individuals: Reactive

 

Anti-mumps IgM

Nonreactive

 

Interpretation

Anti-mumps IgG

Reactive: A reactive result does not differentiate active/past infection from successful vaccination. Seroconversion from non-reactive to reactive is a second specimen is evidence of recent infection or the administration of immunoglobin preparations. In isolated cases, weak-reactive findings may also be caused by cross reactivity to the other human paramyxoviruses e.g. parainfluenza virus type 1, -2, and -3.

 

Non-reactive: No evidence of successful vaccination.

 

Indeterminate: Specimen produced results near the cut-off (indeterminate), please submit a follow up specimen ≥1 week if clinically indicated. Insufficient evidence of successful vaccination.

 

Anti-mumps IgM

Reactive: A reactive result may occur with a recent mumps infection or after vaccination. In the majority of cases IgM remain detectable up to 5 months post infection. Not all mumps virus infections with detectable virus-specific IgM cause clinical symptoms.

 

Non-reactive: A non-reactive result does not exclude early active infection. If clinically indicated submit a follow-up specimen. Anti-mumps IgM may not be detected in previously vaccinated individuals. To confirm active infection virus detection is recommended.

 

Indeterminate: Specimen produced results near the cut-off (indeterminate), please submit a follow up specimen ≥1 week to resolve.

 

Clinical Reference

Litman, N., and Baum, S. G. 2010. Mumps Virus, p. 2201-2206. In Mandell, D., Bennett, J. E., and Dolin, R. Principles and practice of infectious diseases, 7th ed., vol. 2. Churchill Livingstone, Elsevier, Philadelphia, PA.

 

Leland, D. S. 2007. Parainfluenza and Mumps Viruses, p. 1352-1360. In Murray, P. R., Baron, E. J., Jorgensen, J. H., Landry, M. L., and Pfaller, M. A. Manual of Clinical Microbiology, 9th ed., vol. 2. ASM Press, American Society for Microbiology, Washington, DC.

 

Siemens. 2008. Enzygnost® Anti-Parotitis-virus/IgG: package insert. Siemens Healthcare Diagnostics Products GmbH.

 

Status Days Analytic Time Maximum Laboratory Time Specimen Retention
Routine Not routinely done 24h 72h 1 month

Method Description

Enzyme-linked immunosorbent assay (ELISA)

 

Performing Laboratory Location

Newfoundland & Labrador Public Health Laboratory

St. John’s

 

 

 

Latest Updates


Website Downtime - August 14

Oct 29

Due to a datacenter upgrade on August 14, there will be a website outage from 1PM PST - 1AM PST or 5PM AST - 5AM AST. More »


Respiratory and COVID-19 Test Ordering Changes - July 17, 2020

Oct 29

More »

 

Newsletter Signup

Enter your email address below to receive important updates from our labs!